Research & Development
A New Generation of Vaccines
Etubics
is developing the next generation of immunotherapies and vaccines,
utilizing our exclusive Adenovirus Vector Vaccines Platform (AVVP)
technology and our patented human E.C7 cell line to induce both cell
mediated immunity and antibodies. Etubics AVVP technology has been
proven to be safer, more efficient and more effective than current
vectored vaccines.
Etubics is currently developing products to treat or protect against the following diseases:
Therapeutic Vaccines
Preventative Vaccines